Article info
PDFResearch Article
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
- ↵a Eswari.Dodagatta{at}ucsf.edu
- ↵b dominique.meyer{at}idorsia.com
- ↵c melissa.q.reeves{at}gmail.com
- ↵d rpaniagua.md{at}gmail.com
- ↵e minh.dong.to{at}gmail.com
- ↵f mikhail.binnewies{at}gmail.com
- ↵g miranda.broz.1988{at}gmail.com
- ↵h hmori{at}ucdavis.edu
- ↵i di.wu{at}ucsf.edu
- ↵j adoumiem{at}umich.edu
- ↵k Reyno.delrosario{at}ucsf.edu
- ↵l ouming{at}gmail.com
- ↵m tanjabuchmann{at}gmx.at
- ↵n liangbj127{at}hotmail.com
- ↵o Julia.Malato{at}gene.com
- ↵p f.arce{at}ucl.ac.uk
- ↵q Dean.Sheppard{at}ucsf.edu
- ↵r Byron.Hann{at}ucsf.edu
- ↵s amer.m.mirza{at}gmail.com
- ↵t s.quezada{at}ucl.ac.uk
- ↵u Michael.Rosenblum{at}ucsf.edu
- ↵v Matthew.Krummel{at}ucsf.edu
- ↵w allan.balmain{at}ucsf.edu
- ↵x Rosemary.akhurst{at}ucsf.edu
Citation
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
Publication history
- Received October 8, 2018
- Accepted December 20, 2018
- First published March 4, 2019.
Online issue publication
January 08, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.